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Abstract
Background: Tuberculosis (TB) preventive therapy is recommended for all people living with HIV (PLHIV). Despite
the elevated risk of TB amongst PLHIV, most of those eligible for preventive therapy would never develop TB. Tests
which can identify individuals at greatest risk of disease would allow more efficient targeting of preventive therapy.
Methods: We used mathematical modelling to estimate the potential impact of using a blood transcriptomic
biomarker (RISK11) to target preventive therapy amongst PLHIV. We compared universal treatment to RISK11
targeted treatment and explored the effect of repeat screening of the population with RISK11.
Results: Annual RISK11 screening, with preventive therapy provided to those testing positive, could avert 26% (95%
CI 13–34) more cases over 10 years compared to one round of universal treatment. For the cost per case averted to
be lower than universal treatment, the maximum cost of the RISK11 test was approximately 10% of the cost of
preventive therapy. The benefit of RISK11 screening may be greatest amongst PLHIV on ART (compared to ART
naïve individuals) due to the increased specificity of the test in this group.
Conclusions: Biomarker targeted preventive therapy may be more effective than universal treatment amongst
PLHIV in high incidence settings but would require repeat screening.
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Background
Preventive therapy is a key part of tuberculosis (TB)
control that has been shown to significantly reduce the
individual level risk of incident TB [1, 2]. WHO guide-
lines [3] recommend preventive therapy for all adults
and adolescents living with human immunodeficiency
virus (HIV) irrespective of their degree of immunosup-
pression or antiretroviral therapy (ART) status. Despite
these strong recommendations, uptake of preventive
therapy amongst PLHIV remains limited [4].
While there is evidence that PLHIV with prior expos-
ure to Mycobacterium tuberculosis (M.tb), as measured
by tuberculin skin test (TST) or interferon gamma re-
lease assays (IGRA), may gain most benefit from pre-
ventive therapy [2], these tests have poor positive
predictive value for predicting incident TB [5] and may
give false negative results in immunocompromised pa-
tients. Due to this limited predictive performance and
operational barriers to implementing TST and IGRA,
World Health Organization (WHO) recommendations
state that testing for M.tb infection is not required to
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start preventive treatment, especially in high TB inci-
dence settings [3].
However, despite the elevated risk of TB amongst
PLHIV, most of those eligible for preventive therapy
would never develop TB. There is also evidence that in
high TB incidence settings, the duration of protection
from preventive therapy is limited [6–8]. As a result,
universal short-course preventive therapy in PLHIV may
not be the most effective approach to prevent TB. Strat-
egies that could target preventive treatment to individ-
uals at highest risk of developing TB, at the time of
highest risk, may reduce TB incidence and make better
use of resources.
The WHO and the Foundation for Innovative New
Diagnostics (FIND) have developed a target product pro-
file (TPP) for prognostic tests that could predict incident
TB (with minimum and optimum sensitivity and specifi-
city defined as 75% and 90% respectively) [9]. Several
blood transcriptional signatures have been identified as
potential predictors of development of incident disease
[8, 10–13]. The performance of RISK11, an 11-gene
transcriptomic host-response blood signature was re-
cently evaluated in PLHIV in the CORTIS-HR study
[14]. Amongst HIV-positive adults in South Africa,
RISK11 was able to predict progression to TB in those
without prevalent TB at baseline, with sensitivity of 88.6
(43.5–98.7) and specificity of 68.9 (65.3–72.3) over 15
months following screening, approaching the TPP mini-
mum benchmarks. Because preventive therapy for
PLHIV is standard of care in South Africa the trial was
not able to evaluate the benefit of using RISK11 to target
preventive therapy. Mathematical modelling can be used
to estimate the potential effects of RISK11 targeted pre-
ventive therapy, to compare different strategies and to
explore longer time horizons than are possible in clinical
trials.
In this paper, we use a mathematical model, informed
by data from the Correlate of Risk Targeted Intervention
Study in High Risk Populations (CORTIS-HR) [14, 15],
to simulate different strategies for transcriptomic tar-
geted preventive therapy amongst PLHIV. Specifically,
we explore whether repeat transcriptomic screening
followed by short-course preventive therapy may reduce
incidence of TB amongst PLHIV compared to universal




The model, illustrated in Fig. 1, simulates a cohort of
10,000 PLHIV over T years with no prior history of pre-
ventive therapy. The population is split into susceptible
(S), remote infection (L), N recently infected states (LN,
…L1), which track individuals by time until they develop
disease, and those with active TB disease (I). This struc-
ture is used to allow us to incorporate the time horizon
(15 months) of RISK11 performance.
When infected (with probability λ) susceptible individ-
uals are assigned to one of the Li (i = 1,..,N) states or L.
The proportion entering each state (fi, i = 1,…,N) is
based on observations of the cumulative proportion of
individuals who experience disease by time since infec-
tion [16]—details of the calculation of these values are
given in Additional file 1. Each of the Li states is of equal
Fig. 1 Model structure. Solid lines represent transitions between disease states; dashed lines represent transitions on and off preventive therapy. S
= susceptible, L = “remote” infection, Li (i = 1,…,N) = recently infected states (by time to disease), I = active TB disease, Sp = on PT (previously
uninfected), Lp = on PT (previously infected), P = post PT, PT = preventive therapy, λ = risk of infection, fi (i = 1,…,N) = proportion entering infect
state Li following infection, p = relative risk of infection if previously infected, k = risk of progression from remote infection
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duration, D (equal to the time step of the model), after
which individuals progress to the subsequent state (LN
to LN-1 etc.) until they reach the disease state I. Individ-
uals in the L state can progress to the LN state (with
probability k) or be re-infected at a reduced probability,
pλ to represent the protective effect of prior infection
[17]) and move to one of the N recent infection states in
the same proportions as following initial infection. The
cumulative proportion experiencing disease by time
since infection is taken from data in HIV-uninfected
populations and is multiplied by RRHIV to represent the
increased risk of TB amongst PLHIV. Details of the
model parameter values and uncertainty distributions
are given in Table 1.
A proportion (C) of the population is offered prevent-
ive therapy (C will depend on the strategy being consid-
ered (see below)). A proportion, U, of those offered
treatment initiate treatment and amongst those treat-
ment is effective in a proportion E. Those who are ef-
fectively treated move to on treatment states (SP and LP
for those who were susceptible or infected respectively).
While on treatment (for a duration Dp), individuals are
protected from infection or progression to disease. After
treatment susceptible people return to the S state.
People who were previously infected enter a post-
treatment state P. These individuals are not at risk of
progressing to disease but can be re-infected (at a rate
pλ, i.e. they retain the same protection as latently in-
fected individuals).
In our main analysis, we simulated a cohort represen-
tative of the CORTIS-HR study population, where the
prevalence of IGRA positivity (PIGRA) was approximately
45%. We used the prevalence of IGRA positivity together
with the estimated sensitivity (se) [18] and specificity
(sp) [19] of IGRA for M.tb infection to estimate the true
prevalence of infection (PL) using the following
expression:
PL ¼ PIGRA−1þ spse−1þ sp
We then used this estimate of the true prevalence of
infection and the average age of the cohort to calculate
the annual risk of infection (ARI, λ) (assuming a con-
stant life-time risk of infection). The estimated preva-
lence of infection and ARI were then used to define the
initial state of the cohort.
The relative risk of TB disease in PLHIV (RRHIV) was
estimated by fitting the model to the observed incidence
of TB (confirmed by positive Xpert MTB/RIF, Ultra,





Sensitivity of IGRA for infection, se 61 (47–75) [18]
Specificity of IGRA for infection, sp 96 (94–98) [19]
RR of infection if previously infected, p 0.21 (0.14–0.30) [17]
Duration of preventive therapy, Dp 3 months Based on duration of 3HP
Number of recent infection states, N 20 Gives total duration or recent infection of 5 years
Duration of recent infection states, D 3 months
Progression from remote infection, k 1.5e−4 See Additional file 1
Sensitivity for incident TB (over 15months from testing)
RISK11 (whole cohort) 88.6 (43.5–98.7) [14, 15] No incident TB cases amongst RISK11-negative participants not receiving
IPT
RISK11 (on ART and not receiving IPT) 100
RISK11 (ART naïve and not receiving
IPT)
100
Optimum TPP 90 [9]
Minimum TPP 75
Specificity for incident TB (over 15months from testing)
RISK11 (whole cohort) 68.9 (65.3–72.3) [14]
RISK11 (on ART and not receiving IPT) 70.2 (64.0–75.7)
RISK11 (ART naïve and not receiving
IPT)
45.9 (34.9–57.4)
Optimum TPP 90 [9]
Minimum TPP 75
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and/or MGIT culture on at least two separate sputum
samples) over 15 months in the CORTIS-HR study: 0.9
(0.3–1.6) per 100 person years. Full details of the model
fitting are given in Additional file 1. In summary,
100,000 parameter sets were sampled from the distribu-
tions given in Table 1. For each parameter set, the
model was run (with no preventive therapy) to simulate
the incidence of TB over 15 months, and the likelihood
was calculated for each parameter set. One thousand
parameter sets were then resampled with replacement
from the 100,000 samples using the likelihood as weight-
ing for the probability of selecting a given sample.
Preventive therapy strategies
We compare a no treatment scenario to a universal pre-
ventive therapy scenario (a single round of preventive
therapy offered to everyone in the cohort at t = 0) and
to blood transcriptomic targeted therapy. In each case,
we assume treatment is with isoniazid and rifapentine
for 12 weeks (3HP). For the transcriptomic targeted
strategies, we considered three tests: one with character-
istics of the RISK11 assay (from the CORTIS-HR study)
and tests that meet the minimum and optimum criteria
for tests for incipient TB set out in the WHO TPP [9].
The performance characteristics of the tests are given in
Table 1. For each test, we simulated a single round of
screening (at t = 0) or repeat screening with an interval
between screening of 1, 2, or 3 years. Those testing posi-
tive are offered preventive therapy. We assumed that in-
dividuals would only be offered preventive therapy once
(i.e. those testing positive are not retested again irre-
spective of whether they initiate treatment).
We ran the model for 10 years and calculated the
number of people screened, the number given preventive
therapy and the number of TB cases at 5 and 10 years
for each scenario. The incremental impact of test tar-
geted preventive therapy is defined as the ratio of cases
averted by test targeted preventive therapy to cases
averted by universal treatment. Values greater than 1 in-
dicate scenarios where test targeted preventive therapy
averts more cases than universal treatment.
Because the likely programmatic costs of tests for in-
cipient TB are not known we calculated the maximum
cost of a test, as a proportion of the cost of a course of
preventive therapy, such that (a) the total cost of the
strategy with testing does not exceed the cost of the uni-
versal treatment strategy and (b) the cost per case
averted of the strategy with testing does not exceed the
cost per case averted of the universal treatment strategy.
The total costs (T) of the universal (subscript u) and
testing strategies (subscript t) are:
Tu ¼ PuC
Tt ¼ PtC þ StgC
where P = number given preventive therapy; S = number
tested; C = cost of preventive therapy; and g.C = cost of
test (defined relative to the cost of preventive therapy,





The costs per case averted (H) of the universal and
testing strategies are:
Hu ¼ PuCAu
Ht ¼ PtC þ StgCAt
where A = number of cases averted.
Then, for the strategy with a test to be more “cost ef-









Uncertainty in the model parameters was explored by
simulating each preventive therapy strategy for each of
the 1000 parameter sets generated via the fitting process
(see above). For each parameter sample, values for the
RISK11 test performance were sampled from the distri-
butions in Table 1. To identify the parameters that con-
tribute to uncertainty in the model outputs, we
calculated partial rank correlation coefficients (PRCCs)
for the sampled parameters considering the ratio of
cases averted and the maximum cost of the test (per case
averted) as outputs.
In the CORTIS-HR study, the performance of RISK11
in PLHIV was found to vary by ART status and whether
or not individuals received IPT during the study. To as-
sess the impact of these differences on the model predic-
tions, we carried out additional model simulations using
sensitivity and specificity estimates for RISK11 based on
analysis of participants who did not receive IPT during
the study, stratified by ART status at enrolment in the
study (see Table 1). For these sub-group analyses, RRHIV
was re-estimated by fitting the model to the observed in-
cidence amongst either those on ART at enrolment (0.3
per 100 person-years; 95% CI 0.0–1.0) or amongst the
ART naïve population (4 per 100 person-years; 95% CI
0.1–7.7). As many of those who were ART naive at en-
rolment initiated ART during the trial (~ 75%), reducing
their risk of TB and potentially changing the perform-
ance of future RISK11 screening, we also explored a
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scenario in which the sensitivity and specificity of
RISK11 and value of RRHIV were varied in the model
from the ART naïve cohort values to those of the ART
cohort after 1 year.
In the main analysis, we assumed that uptake (U) was
100% and did not depend on whether testing was carried
out. We also assumed that the efficacy of treatment was
the same in those testing positive or negative in screen-
ing. Because we consider all outputs relative to universal
treatment, they do not depend on the absolute value of
treatment efficacy (E). Similarly, the incremental impact
of test targeted treatment does not depend on uptake
but the costs are proportional to the uptake.
Results from the CORTIS study [8], which evaluated
the diagnostic and prognostic performance of RISK11,
and the efficacy of 3HP for preventing TB in RISK11-
positive, HIV-uninfected adults found that 3HP did not
reduce the incidence of TB amongst RISK11-positive in-
dividuals. No data is available on the efficacy of 3HP in
RISK11-positive PLHIV. To explore the possible effects
of reduced efficacy of 3HP in RISK11-positive PLHIV,
we carried out simulations, varying the relative efficacy
of 3HP in true positive, RISK11-positive PLHIV (com-
pared to RISK11 negative) from 0 to 100%. This reduced
efficacy was also applied in the universal treatment sce-
nario to the subset of individuals who would have been
RISK11 positive.
To further explore how the results depend on the TB
disease burden we re-ran the model for combinations of
the prevalence of infection (0–100%) and ARI (0–5% per
year).
Results
Figure 2 shows the results for our main analysis of the
CORTIS-HR cohort, assuming uptake of preventive
therapy of 100% and equal efficacy in RISK11-positive
and RISK11-negative individuals. Based on the preva-
lence of IGRA positivity in the trial cohort, the estimated
prevalence of infection was 71% (95% CI 59–93) and the
ARI was 3.6% (95% CI 2.4–7.5).
Test targeted treatment would avert at least as many
cases as universal treatment with an annual screening
interval (over a 5-year time horizon) or with a screening
interval of 2 years or less (over a 10-year horizon). An-
nual RISK11 screening could avert 22% (95% CI 6–31)
more cases over 5 years and 26% (95% CI 13–34) over
10 years compared to universal treatment.
With annual RISK11 screening, the test would have to
cost less than 6% (95% CI 5–7) of the cost of preventive
therapy (5-year horizon) or less than 1% (95% CI 0.6–
1.3) of the cost of preventive therapy (10-year horizon)
for the total cost of the intervention to be less than uni-
versal treatment. However, when accounting for the add-
itional cases averted with annual RISK11 screening, the
possible cost of the test is increased. The RISK11 test
could cost up to 14% (95% CI 8–17) of the cost of pre-
ventive therapy (5-year horizon) or 9% (95% CI 5–12) of
the cost of preventive therapy (10-year horizon) for the
cost per case averted to be less than universal treatment.
Calculation of partial rank correlation coefficients
(PRCCs) shows that with a single round of screening,
the results are most sensitive to the sensitivity and speci-
ficity of RISK11. As expected, a more sensitive and less
specific test would avert more cases while a more sensi-
tive and more specific test would result in a higher po-
tential cost for the test. With repeat screening, the
relative protective effect of prior infection is increasingly
important, indicating that the risk of TB after preventive
therapy is important in determining the effect of a
screening based strategies. PRCCs are shown in figure
Additional file 1 L: Fig S3.
Annual screening with a test satisfying the minimum
TPP characteristics (75% sensitivity and specificity) pre-
vents fewer cases than RISK11 (due to the lower sensi-
tivity) but uses less preventive therapy (due to the higher
specificity). The median cost of such a test is lower than
RISK11; however, the confidence intervals overlap. A
test satisfying the optimum TPP (90% sensitivity and
specificity) could cost approximately 25% of the cost of
preventive therapy (5-year horizon) or 16% of the cost of
preventive therapy (10-year horizon) for the cost per
case averted to be less than universal treatment.
As these results are calculated relative to universal
treatment, they do not depend on the value of treatment
efficacy (E) used assuming efficacy is the same by
RISK11 status. If the efficacy of treatment is lower
amongst RISK11 positives, the incremental benefit of
RISK11 screening compared to universal treatment is
lower and the test would have to cost less. Figure 3
shows how the ratio of cases averted (compared to uni-
versal treatment) and the cost of testing for annual
RISK11 screening vary with the relative efficacy of 3HP
in RISK11-positive PLHIV. For RISK11 targeted treat-
ment to avert more cases over a 10-year horizon, the
relative efficacy must be greater than 47%. The cost re-
sults also depend on the assumed uptake of preventive
therapy. With lower uptake the number of courses of
preventive therapy saved by RISK11 screening is greater
and so the maximum relative cost of the test is lower;
this relationship is linear, i.e. for an uptake of 75%, the
cost per case averted would be 75% of that with 100%
uptake.
Figure 4 shows the results for the sub-group analysis
of those who did not receive IPT during the CORTIS-
HR study stratified by ART status at enrolment. Annual
RISK11 screening is more effective than universal treat-
ment in all sub-groups. However, the incremental bene-
fit of annual RISK11 screening (compared to universal
Sumner et al. BMC Medicine          (2021) 19:252 Page 5 of 11
treatment) is greater in those on ART than in ART naïve
individuals and uses less preventive therapy (due to the
higher specificity of RISK11 in people on ART). As a re-
sult, the test could cost more (relative to the cost of pre-
ventive therapy) when used in individuals on ART (12%
(95% CI 10–14)).
Figure 5 shows the ratio of cases averted by annual
RISK11 targeted preventive therapy compared to univer-
sal treatment, for different values of prevalence of infec-
tion and ARI. Figure 6 shows the maximum cost of the
RISK11 test (per case averted). The lower the prevalence
of infection the greater the incremental benefit of
Fig. 2 Results by test type and testing interval. Points show median model output; bars show 95% range of model outputs. Colours indicate
different tests (see key). Top row: ratio of cases averted (compared to universal treatment). Second row: cumulative number screened. Third row:
cumulative number given 3HP. Fourth row: maximum cost of test (relative to 3HP) such that total cost does not exceed cost of universal
treatment. Fifth row: maximum cost of test (relative to 3HP) such that cost per case averted does not exceed cost per case averted of universal
treatment. Left panel: after 5 years; right panel: after 10 years
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RISK11 targeted preventive therapy and the more the
test can cost. This is because, at a low prevalence, there
are fewer infected individuals who benefit from universal
preventive therapy. Conversely, the higher the ARI the
more additional cases are averted by RISK11 targeted
screening and the more the test can cost. This is be-
cause, at a higher ARI, more individuals would be in-
fected after universal treatment and there is greater
benefit from using RISK11 to target treatment at a later
time.
Discussion
Our results suggest that targeting short-course prevent-
ive therapy in PLHIV based on repeat transcriptomic
screening could prevent more incident TB cases than a
single round of universal treatment as recommended by
WHO. Current WHO guidelines recommend that all
PLHIV should be offered preventive therapy and that
testing for M.tb infection is not a pre-requisite for initi-
ating treatment. National guidelines vary, but in South
Africa, the location of the CORTIS-HR study, the rec-
ommendation is also that all PLHIV are eligible for
treatment with the duration of therapy dependent on
TST status. In a high TB incidence setting, such as
South Africa, screening would need to be conducted at
least biennially to be more effective than universal treat-
ment over 10 years. The use of transcriptomic testing
would also require fewer people to be treated with pre-
ventive therapy—the total number treated only ap-
proaches the total population with annual screening
over a 10-year time horizon. Given the extra cases
averted and reduction in the number treated, the cost of
testing could be approximately 10% of the cost of pre-
ventive therapy for annual screening to be more cost-
effective (cost per case averted) compared to universal
treatment. Assuming a full cost of 3HP of approximately
70 USD in South Africa [20], the cost of testing could be
on the order of 7 USD. For comparison, the cost of a
prognostic test defined in the TPP (minimal characteris-
tics) was 10–100 USD [9].
Our results do not depend on the absolute level of effi-
cacy of preventive therapy assuming treatment is equally
efficacious in RISK11-positive and RISK11-negative indi-
viduals. However, if treatment is less effective in
RISK11-positive individuals, the benefit of targeted pre-
ventive therapy is reduced; with a relative efficacy of
below 47%, annual RISK11 screening becomes less ef-
fective than universal treatment. The CORTIS study [8],
Fig. 3 Results by relative efficacy of preventive therapy in RISK11-positive individuals. Solid lines show median model output; shaded regions
show 95% range of model outputs. Colours indicate different time horizons (see key). Left panel: ratio of cases averted (compared to universal
treatment). Right panel: maximum cost of test (relative to 3HP) such that cost per case averted does not exceed cost per case averted of
universal treatment
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which evaluated the diagnostic and prognostic perform-
ance of RISK11 in HIV-uninfected adults, found that
RISK11 targeted preventive therapy with 3HP did not re-
duce the risk of incident TB through 15months follow
up; however, there were no incident TB cases through 9
months in adherent RISK11-positive participants who
completed at least 11 out of 12 observed doses of once-
weekly isoniazid-rifapentine within 16 weeks suggesting
a short term benefit of 3HP in this population. No data
is available on the efficacy of treatment in RISK11-
positive, HIV-infected populations.
In our analysis, we have assumed that uptake and
completion of preventive therapy does not depend on
testing. It is possible that uptake and completion may
be influenced by testing. For example, data from the
US suggests that individuals tested with IGRA had in-
creased rates of preventive therapy completion
compared to those tested with TST [21]. However, it
is also possible that testing may reduce uptake if
there is a delay between testing and availability of test
results.
We found that the additional benefit of RISK11 tar-
geted treatment and the potential cost of the test depend
on the prevalence of infection and the annual risk of in-
fection. The model suggests that for an ARI above 1%,
annual screening with RISK11 would avert more cases of
TB than universal treatment for any prevalence of infec-
tion. The maximum relative cost for a test, across the
range of ARI and prevalence considered, was 27% of the
cost of a course of preventive therapy, providing a po-
tential upper bound on the costs.
Previous studies have compared the cost-
effectiveness of TST or IGRA targeted preventive
therapy to untargeted treatment in PLHIV [22–24]
Fig. 4 Results by ART status amongst individuals not receiving IPT during the CORTIS-HR study. Points show median model output, bars show
95% range of model outputs. Colours indicate ART status (see key). Top row: ratio of cases averted (compared to universal treatment). Second
row: cumulative number screened. Third row: cumulative number given 3HP. Fourth row: maximum cost of test (relative to 3HP) such that total
cost does not exceed cost of universal treatment. Fifth row: maximum cost of test (relative to 3HP) such that cost per case averted does not
exceed cost per case averted of universal treatment. Left panel: after 5 years; right panel: after 10 years
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but have not considered longer term dynamics or re-
peat screening. Data from Hong Kong showed limited
benefit of repeat testing for infection amongst PLHIV
[25] potentially due to the declining risk of TB over
time associated with ART driven immune-recovery.
We have assumed the risk of developing TB remained
constant over time which may overestimate the
benefit of repeat RISK11 screening. However, this
study was also conducted in a low-incidence commu-
nity setting where the risk of infection after initial
testing is low. This would also limit any benefit of re-
peat testing, consistent with our result that the add-
itional benefit of annual RISK11 screening would be
lower at lower ARIs.
Fig. 5 Ratio of cases averted by annual RISK11 targeted preventive therapy compared to universal treatment by prevalence of infection (x-axis)
and annual risk of infection (y-axis). Left panel: after 5 years; right panel: after 10 years. Black lines show the contour where the ratio = 1. Black
dots indicate the median prevalence and ARI assumed in the CORTIS-HR cohort (Fig. 2)
Fig. 6 Maximum cost of RISK11 test (relative to 3HP) such that the cost per case averted does not exceed the cost per case averted of universal
treatment by prevalence of infection (x-axis) and annual risk of infection (y-axis). Left panel: after 5 years; right panel: after 10 years. Black dots
indicate the median prevalence and ARI assumed in the CORTIS-HR cohort (Fig. 2)
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We assumed that individuals would only receive a sin-
gle course of preventive therapy as there is limited data
on the effect of repeated courses of preventive treat-
ment. A trial in South Africa, Ethiopia, and Mozambique
found no additional benefit of universal annual 3HP
(compared to a single course of treatment) amongst
PLHIV on ART [26]. However, targeted annual prevent-
ive therapy to those at highest risk of progression to TB
disease (ART naïve, low CD4) has not been explored.
We have only considered the direct effects of prevent-
ive therapy and not the indirect benefit of reductions in
TB incidence on onward transmission. We only consid-
ered the costs saved from reduced use of preventive
therapy when calculating the maximum relative costs of
testing. However, there are potential additional cost sav-
ings of annual RISK11 screening due to the increased
number of TB cases averted and the resulting reduction
in costs of treating active TB. Finally, we do not consider
the potential benefit of identifying undiagnosed preva-
lent TB during RISK11 screening. Guidelines recom-
mend the use of symptom screening to exclude
prevalent disease before initiation of preventive therapy
[3]; however, data from the CORTIS-HR study found
that symptom screening missed approximately 70% of
prevalent cases while RISK11 had sensitivity of 87.5
(58.3–100) for undiagnosed prevalent disease.
Conclusion
Biomarker targeted preventive therapy may be more ef-
fective than one-off of universal treatment amongst
PLHIV in high incidence settings but would require re-
peat screening. Assuming annual screening, testing
would have to cost on the order of one tenth the cost of
the preventive therapy regimen to be more cost-effective
than one-off universal treatment.
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